New molecular markers were further tested in appropriate cell lines to confirm their role. We gave special attention to the mechanisms of multi-drug resistance, and the potential for its overcoming. Therefore, we developed new multi-drug resistant human and animal cell lines to study the anticancer effects and the mechanisms of a wide range of new natural products, as well as synthetic and semi-synthetic agents. Clinical research includes clinical trials phase II and III, as well as a retrospective study of rare tumors. In theoretical studies, we engaged biophysical analysis in order to define the molecular profile of patients and mathematical models of resistance to chemotherapy. By identifying the molecular changes, defining their contribution to the cancer evolution, by translation into clinical practice and by development of new, more effective drugs, our project should contribute to the achievement of optimal individual therapy for cancer patients.

Project team:

Dr. Nikola Tanić, project leader

This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Milica Pešić

Dr. Tijana Stanković

Dr. Jelena Dinić

Dr. Ana Podolski-Renić

Dr. Katarina Hofman

Dr. Miodrag Dragoj

Marija Nešović

Mirna Jovanović

External Associate:

This email address is being protected from spambots. You need JavaScript enabled to view it.

School of Medicine, University of Belgrade:

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Institute for Oncology and Radiology of Serbia, Belgrade:

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.

This email address is being protected from spambots. You need JavaScript enabled to view it.